{
    "nct_id": "NCT04323657",
    "official_title": "Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)",
    "inclusion_criteria": "* Patient is > 18 years of age at the time the Informed Consent is signed\n* Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU\n* Histologically confirmed NHL or ALL\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol\n* Patient must be fit for leukapheresis and have adequate venous access for cell collection\n* Patient must have evidence of CD19 expression\n* Prior CD19-directed CAR T therapy is allowed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}